Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • Maxcyte's Share-based Compensation fell 4201.78% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 1391.7%. This contributed to the annual value of $13.1 million for FY2024, which is 640.96% down from last year.
  • According to the latest figures from Q3 2025, Maxcyte's Share-based Compensation is $2.0 million, which was down 4201.78% from $3.5 million recorded in Q2 2025.
  • Maxcyte's 5-year Share-based Compensation high stood at $3.6 million for Q3 2023, and its period low was $1.3 million during Q1 2021.
  • For the 5-year period, Maxcyte's Share-based Compensation averaged around $2.9 million, with its median value being $3.1 million (2022).
  • Per our database at Business Quant, Maxcyte's Share-based Compensation skyrocketed by 28217.39% in 2021 and then tumbled by 4201.78% in 2025.
  • Maxcyte's Share-based Compensation (Quarter) stood at $2.4 million in 2021, then grew by 27.36% to $3.1 million in 2022, then grew by 14.62% to $3.6 million in 2023, then dropped by 12.31% to $3.1 million in 2024, then tumbled by 37.65% to $2.0 million in 2025.
  • Its Share-based Compensation stands at $2.0 million for Q3 2025, versus $3.5 million for Q2 2025 and $3.0 million for Q1 2025.